Murray M, O'Briain D S, Prichard J, McCann S R
Ir J Med Sci. 1989 Feb;158(2):36-9. doi: 10.1007/BF02942059.
Bone marrow transplantation is the treatment of choice of many haematological disorders but its success is limited by two major complications, graft-versus-host disease (GVHD) and pulmonary disorders. Of the first 31 patients transplanted at St. James's Hospital (1984-1986) 16 (52%) had a successful outcome. Of the 15 patients who died, two died of GVHD and one of recurrent leukaemia. All others had severe pulmonary disease either causing death directly (9 cases) or contributing to death from toxic encephalopathy, carditis or recurrent leukaemia (1 case each). The principal forms of pulmonary disease were cytomegalovirus pneumonitis (4 cases), acute haemorrhagic pulmonary oedema (4 cases) and pneumocystis carinii pneumonia (2 cases). There were single cases of staphylococcal pneumonia and idiopathic pulmonary fibrosis. Aspergillus was a second pathogen in two cases. Pulmonary damage due to conditioning chemoradiotherapy and to GVHD probably underlies this high incidence of pulmonary disease. T-cell depletion to limit the incidence of GVHD together with increased prophylaxis against CMV and pneumocystis carinii will probably substantially reduce these complications in the near future.
骨髓移植是许多血液系统疾病的首选治疗方法,但其成功率受到两种主要并发症的限制,即移植物抗宿主病(GVHD)和肺部疾病。在圣詹姆斯医院(1984 - 1986年)接受移植的首批31例患者中,16例(52%)获得了成功的结果。在15例死亡患者中,2例死于GVHD,1例死于复发性白血病。所有其他患者都患有严重的肺部疾病,要么直接导致死亡(9例),要么导致因中毒性脑病、心肌炎或复发性白血病死亡(各1例)。肺部疾病的主要形式是巨细胞病毒性肺炎(4例)、急性出血性肺水肿(4例)和卡氏肺孢子虫肺炎(2例)。有1例金黄色葡萄球菌肺炎和1例特发性肺纤维化。曲霉菌是2例患者的第二种病原体。预处理放化疗和GVHD导致的肺部损伤可能是这种高发病率肺部疾病的根本原因。在不久的将来,减少T细胞以限制GVHD的发生率,同时加强对巨细胞病毒和卡氏肺孢子虫的预防,可能会大幅降低这些并发症的发生。